Cholesterol Efflux Assay Kit (Cell-based) (ab196985)
Key features and details
- Assay type: Cell-based (quantitative)
- Detection method: Fluorescent
- Platform: Microplate reader
- Sample type: Adherent cells, Purified protein
Overview
-
Product name
Cholesterol Efflux Assay Kit (Cell-based) -
Detection method
Fluorescent -
Sample type
Adherent cells, Purified protein -
Assay type
Cell-based (quantitative) -
Species reactivity
Reacts with: Mammals, Other species -
Product overview
Cholesterol Efflux Assay Kit ab196985 is a high-throughput, cell-based screening assay for measuring cholesterol efflux. The cholesterol efflux assay protocol uses fluorescently-labeled cholesterol (Ex/Em 482/515 nm). It provides a safe, sensitive and reproducible method for measuring cholesterol efflux.
This cholesterol efflux assay can be used to:
- screen small molecules for their effect on cholesterol efflux as a part of drug discovery program.
Cholesterol efflux assay protocol summary:
- label cells with labeling and equilibration mix overnight
- wash cells, treat as required and incubate
- transfer cell supernatant to microplate, and separately solubilize cells with cell lysis buffer
- analyze supernatant and cell lysates with microplate reader -
Notes
Cholesterol efflux from the peripheral tissues and cells in atherosclerotic plaque is an initial and critical step in Reverse Cholesterol Transport (RCT). RCT is the process by which extra hepatic cells, including macrophage-derived foam cells in arterial atherosclerotic plaque, transport excessive cholesterol back to the liver for bile acid synthesis and excretion, thus lowering the peripheral lipid burden.
Other cholesterol assay kits include:
- HDL and LDL/VLDL Cholesterol assay kit ab65390
- Cell-based Cholesterol assay kit ab133116
- Cholesterol/Cholesterol Ester assay kit ab65359
- Cholesterol Uptake assay kit ab236212Abcam has not and does not intend to apply for the REACH Authorisation of customers’ uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses. -
Platform
Microplate reader
Properties
-
Storage instructions
Store at -20°C. Please refer to protocols. -
Components 100 tests Cell Lysis Buffer 1 x 20ml Equilibration Buffer 1 x 5ml Labeling Reagent 1 x 5ml Positive Control 1 x 1ml Reagent A 1 x 10µl Reagent B 1 x 50µl Serum Treatment Reagent 1 x 1ml -
Research areas
Images
-
Percentage Cholesterol Efflux
J774.1 cells were labeled with the Labeling Media and treated with various cholesterol acceptors like Human Serum, HDL (50 µg) or Positive control known to cause cholesterol efflux. Cholesterol efflux is expressed as % efflux elicited by cells in 4 hours.
Datasheets and documents
-
SDS download
-
Datasheet download
References (12)
ab196985 has been referenced in 12 publications.
- Yusuf B et al. The neurorepellent, Slit2, prevents macrophage lipid loading by inhibiting CD36-dependent binding and internalization of oxidized low-density lipoprotein. Sci Rep 11:3614 (2021). PubMed: 33574432
- Almowallad S et al. Punicalagin Regulates Key Processes Associated with Atherosclerosis in THP-1 Cellular Model. Pharmaceuticals (Basel) 13:N/A (2020). PubMed: 33171640
- Ravodina AM et al. Facile Cholesterol Loading with a New Probe ezFlux Allows for Streamlined Cholesterol Efflux Assays. ACS Omega 5:23289-23298 (2020). PubMed: 32954180
- Lv JJ et al. Blockade of Macrophage CD147 Protects Against Foam Cell Formation in Atherosclerosis. Front Cell Dev Biol 8:609090 (2020). PubMed: 33490072
- Shih CM et al. Dysfunctional high density lipoprotein failed to rescue the function of oxidized low density lipoprotein-treated endothelial progenitor cells: a novel index for the prediction of HDL functionality. Transl Res 205:17-32 (2019). PubMed: 30720435